Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Initiation

Initiation

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Scotiabank Initiates Coverage On Illumina with Sector Perform Rating, Announces Price Target of $216

By Benzinga Newsdesk
January 5, 6:00 AM
Scotiabank analyst Sung Ji Nam initiates coverage on Illumina (NASDAQ:ILMN) with a Sector Perform rating and announces Price Target of $216.

ILMN

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Scotiabank Initiates Coverage On Twist Bioscience with Sector Outperform Rating, Announces Price Target of $33

By Benzinga Newsdesk
January 5, 5:58 AM
Scotiabank analyst Sung Ji Nam initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Sector Outperform rating and announces Price Target of $33.

TWST

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Scotiabank Initiates Coverage On Bionano Genomics with Sector Outperform Rating, Announces Price Target of $4

By Benzinga Newsdesk
January 5, 5:56 AM
Scotiabank analyst Sung Ji Nam initiates coverage on Bionano Genomics (NASDAQ:BNGO) with a Sector Outperform rating and announces Price Target of $4.

BNGO

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Scotiabank Initiates Coverage On Castle Biosciences with Sector Outperform Rating, Announces Price Target of $54

By Benzinga Newsdesk
January 5, 5:53 AM
Scotiabank analyst Sung Ji Nam initiates coverage on Castle Biosciences (NASDAQ:CSTL) with a Sector Outperform rating and announces Price Target of $54.

CSTL

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Scotiabank Initiates Coverage On Pacific Biosciences with Sector Outperform Rating, Announces Price Target of $12

By Benzinga Newsdesk
January 5, 5:52 AM
Scotiabank analyst Sung Ji Nam initiates coverage on Pacific Biosciences (NASDAQ:PACB) with a Sector Outperform rating and announces Price Target of $12.

PACB

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

DA Davidson Initiates Coverage On Microsoft with Buy Rating, Announces Price Target of $270

By Benzinga Newsdesk
January 5, 5:50 AM
DA Davidson analyst Gil Luria initiates coverage on Microsoft (NASDAQ:MSFT) with a Buy rating and announces Price Target of $270.

MSFT

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

EF Hutton Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $10

By Benzinga Newsdesk
January 5, 5:46 AM
EF Hutton analyst Tony Butler initiates coverage on Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy rating and announces Price Target of $10.

ADAP

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

EF Hutton Initiates Coverage On Rain Oncology with Buy Rating, Announces Price Target of $16

By Benzinga Newsdesk
January 5, 5:44 AM
EF Hutton analyst Tony Butler initiates coverage on Rain Oncology (NASDAQ:RAIN) with a Buy rating and announces Price Target of $16.

RAIN

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

EF Hutton Initiates Coverage On Merus with Buy Rating, Announces Price Target of $35

By Benzinga Newsdesk
January 5, 5:42 AM
EF Hutton analyst Tony Butler initiates coverage on Merus (NASDAQ:MRUS) with a Buy rating and announces Price Target of $35.

MRUS

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

EF Hutton Initiates Coverage On G1 Therapeutics with Buy Rating, Announces Price Target of $35

By Benzinga Newsdesk
January 5, 5:39 AM
EF Hutton analyst Tony Butler initiates coverage on G1 Therapeutics (NASDAQ:GTHX) with a Buy rating and announces Price Target of $35.

GTHX

Posts pagination

Previous 1 … 100 101 102 … 272 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service